Brain derived neurotrophic factor in multiple sclerosis: Effect of 24 weeks endurance and resistance training

European Journal of Neurology

Volumn 23, Issue 6, 2016, Pages 1028-1035

  Wens, I ^a   Keytsman, C ^a   Deckx, N ^b   Cools, N ^b   Dalgas, U ^c   Eijnde, B O ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Brain derived neurotrophic factor; Combined exercise; Endurance and resistance training; Healthy controls; Multiple sclerosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ENDURANCE; ENDURANCE TRAINING; EXERCISE TOLERANCE; EXPANDED DISABILITY STATUS SCALE; FAT MASS; FEMALE; HUMAN; LEAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; PRIORITY JOURNAL; RESISTANCE TRAINING; BLOOD; BODY COMPOSITION; EXERCISE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BODY COMPOSITION; BRAIN-DERIVED NEUROTROPHIC FACTOR; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; RESISTANCE TRAINING; TREATMENT OUTCOME;

EID: 84961266587     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12976     Document Type: Article

References (34)

1. Frota ER, Rodrigues DH, Donadi EA, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009; 460: 130-132.
2. Rojas VS, Struder HK, Vera WB, et al. Acute BDNF and cortisol response to low intensity exercise and following ramp incremental exercise to exhaustion in humans. Brain Res 2006; 1121: 59-65.
3. Rasmussen P, Brassard P, Adser H, et al. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009; 94: 1062-1069.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
5. Matthew Sorenson, Leonard Jason, Jonna Peterson, et al. Brain derived neurotrophic factor is decreased in chronic fatigue syndrome and multiple sclerosis. J Neurol Neurophysiol 2014; S12: 1-6.
6. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008; 195: 186-193.
7. Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing-remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005; 167: 215-218.
8. Stuifbergen AK. Physical activity and perceived health status in persons with multiple sclerosis. J Neurosci Nurs 1997; 29: 238-243.
9. White LJ, Dressendorfer RH. Exercise and multiple sclerosis. Sports Med 2004; 34: 1077-1100.
10. Gold SM, Schulz KH, Hartmann S, et al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 2003; 138: 99-105.
11. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002; 25: 295-301.
12. Ferris LT, Williams JS, Shen CL. The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc 2007; 39: 728-734.
13. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res 2015; 60: 56-64.
14. Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Disord 2012; 5: 81-95.
15. Doring A, Pfueller CF, Paul F, et al. Exercise in multiple sclerosis - an integral component of disease management. EPMA J 2011; 3: 2.
16. Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int 2014; 2014: 798285.
17. Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005; (1): CD003980.
18. Wens I, Dalgas U, Stenager E, et al. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Mult Scler 2013; 19: 1556-1564.
19. Wens I, Hansen D, Verboven K, et al. Impact of 24 weeks of resistance and endurance exercise on glucose tolerance in persons with multiple sclerosis. Am J Phys Med Rehabil 2015; 94(10 Suppl 1): 838-847.
20. Schulz KH, Gold SM, Witte J, et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci 2004; 225: 11-18.
21. Castellano V, White LJ. Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis. J Neurol Sci 2008; 269: 85-91.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
23. 2, heart rate and muscle deoxygenation kinetics affected by serial moderate-intensity exercise transitions in a single day? Eur J Appl Physiol 2011; 111: 591-600.
24. Jones NL, Makrides L, Hitchcock C, et al. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 1985; 131: 700-708.
25. 2 kinetics during submaximal endurance exercise in subjects with multiple sclerosis. Neurorehabil Neural Repair 2013; 27: 87-95.
26. Vacaras V, Major ZZ, Muresanu DF, et al. Effect of glatiramer acetate on peripheral blood brain-derived neurotrophic factor and phosphorylated TrkB levels in relapsing-remitting multiple sclerosis. CNS Neurol Disord Drug Targets 2014; 13: 647-651.
27. Ruggieri M, Avolio C, Livrea P, et al. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev 2007; 13: 178-191.
28. Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 2007; 13: 313-331.
29. Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006; 406: 270-275.
30. Kjolhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training: a systematic review. Mult Scler 2012; 18: 1215-1228.
31. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432-441.
32. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler 2008; 14: 35-53.
33. Carter P, White CM. The Effect of General Exercise Training on Effort of Walking in Patients with Multiple Sclerosis. 14th International World Confederation for Physical Therapy, Barcelona, 2003; RR-PL-1517.
34. Motl RW, Smith DC, Elliott J, et al. Combined training improves walking mobility in persons with significant disability from multiple sclerosis: a pilot study. J Neurol Phys Ther 2012; 36: 32-37.